Ann: Notification of upcoming expiry of Unlisted Options, page-78

You have absolutely zero understanding of marketing else you won't be throwing these nonsense theories.

New pathways in clinical treatments gets changed time and time again if data shows improvements in biomarkers...

Travere MC at its peak close to 3bn USD (AUD 4.5bn), with a successful DUPLEX study, it would have touched 7-8bn.

Travere still have a massive institutional ownership, institutions do their due diligence before putting their money in. They know very well where the drug will play a role....atleast more than a bullshitter who gets his advice from a "Doctor" friend (I am sure your doctor is a Snake Charmer)

Look at some of the names:

"Travere Therapeutics, Inc. (US:TVTX) has 358 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 93,838,409 shares. Largest shareholders include BlackRock Inc., Armistice Capital, Llc, Deep Track Capital, LP, Vanguard Group Inc, State Street Corp, Macquarie Group Ltd, Morgan Stanley, XBI - SPDR(R) S&P(R) Biotech ETF, DCCAX - Delaware Small Cap Core Fund Class A, and Renaissance Technologies Llc "

So stop your bullshit posts and go marry a Donkey...